# Talaris Therapeutics (stock symbol: TALS) Logo in transparent PNG and SVG formats

## Talaris Therapeutics Logo large

### Talaris Therapeutics Logo large Download PNG (82.27 KB)

![Talaris Therapeutics Logo large Download PNG (82.27 KB)](/img/orig/TALS_BIG-515da390.png)

### Talaris Therapeutics Logo large Download SVG (11.13 KB)

![Talaris Therapeutics Logo large Download SVG (11.13 KB)](/img/orig/TALS_BIG-d5d60c70.svg)

## Talaris Therapeutics Logo icon format

### Talaris Therapeutics Logo icon format Download PNG (83.93 KB)

![Talaris Therapeutics Logo icon format Download PNG (83.93 KB)](/img/orig/TALS-90f0bd6e.png)

### Talaris Therapeutics Logo icon format Download SVG (4.41 KB)

![Talaris Therapeutics Logo icon format Download SVG (4.41 KB)](/img/orig/TALS-79badcaf.svg)

## About Talaris Therapeutics

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

1. Website domain: talaristx.com
2. Employees: 128
3. Marketcap: $0.12 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
